Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Shareholder Meeting (November 2022)
24 slides from Chimeric Therapeutics's shareholder meeting presentation, Nov 15, 2022
Slide 1: Annual General Meeting
For personal use only Annual General Meeting Jennifer Chow CEO and Managing Director November 15, 2022
Slide 2: Disclaimer
DISCLAIMER For personal use only Certain statements contained in this presentation, including, information or studies to be completed or provided prior to their without limitation, statements containing the words “believes,” approval of our products. “plans,” “expects,” “anticipates,” and words of s
Slide 3: Committed to Bringing the Promise of Cell Therapy to Life
For personal use only COMMITTED Traditional drug development focuses on delaying TO BRINGING disease progression - not on a cure. THE PROMISE We believe that novel cellular therapies have the promise to cure cancer. OF CELL To bring that promise to life for more patients, the THERAPY TO mission of C
Slide 4: We can now conclude that CAR-T cells can cure patients with leukemia
4 “We can now conclude that For personal use only CAR-T cells can CURE patients with leukemia” Dr Carl June, MD Richard W. Vague Professor in Immunotherapy Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine
Slide 5: Cell Therapy Anticipated to Be the Fastest Growing Market in Oncology
CELL THERAPY 5 ANTICIPATED TO BE THE FASTEST GROWING MARKET IN ONCOLOGY For personal use only 2022 2027 MARKET MARKET CAGR $265 BN ONCOLOGY $581BN ONCOLOGY 8.2% ONCOLOGY $10.69 BN CELL THERAPY $42.37BN CELL THERAPY 31.7% CELL THERAPY Market Data Forecast, Global Cell Therapy Market Size, Share, Tren
Slide 6: Chimeric Therapeutics Corporate Snapshot
CHIMERIC THERAPEUTICS CORPORATE SNAPSHOT For personal use only • Multiple Assets with Positive Phase ASX: CHM 1 Signals 0.31 Share Price AUS ($) • Robust Clinical Development Plans with Broad Therapeutic Focus 0.16 0.12 0.14 • Innovative and Diversified Portfolio 0.08 of Next Generation Technologies
Slide 7: A Year of Major Milestones: November 2021 - November 2022
A YEAR OF MAJOR MILESTONES: November 2021- November 2022 For personal use only CORE NK Option CDH17 CAR T CORE NK CDH17 VECTOR CORE NK (CHM 0201) (CHM 2101) (CHM 0201) (CHM 2101) (CHM 0201) From Case Western Sponsored Research Exercise of Licensed from University Sponsored Research Reserve Universit
Slide 8: Chimeric Cell Therapy Portfolio
CHIMERIC CELL THERAPY PORTFOLIO CUTTING EDGE INNOVATION WITH BROAD COMMERCIAL OPPORTUNITY For personal use only Novel Design T Cells NK Cells Autologous Allogeneic (personal) (off-the-shelf) CORE-NK Platform Phase 1 Complete CLTX CAR T CLTX CAR T CDH17 CAR T (ICT/ ICV) (IV) Next Gen. CLTX CDH17 Undi
Slide 9: Differentiating Chimeric
DIFFERENTIATING CHIMERIC A DIVERSIFIED PORTFOLIO WITH A FOCUS ON CURATIVE INTENT For personal use only Cancer Target Innovation T Cell Derived Therapies NK Cell Derived Therapies Personalized (Autologous) Therapies Off the Shelf (Allogeneic) Therapies
Slide 10: Chimeric Management Team
CHIMERIC MANAGEMENT TEAM EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION For personal use only EXPERIENCE EXPERTISE PROVEN 75+ 50+ 4/6 Years of Cell Development Of the Therapy Experience FDA-Approved Programs CAR T Cell Therapies Dr Jason Dr Li Dr Stephanie Dr Eliot Kelly Cassandra LITTEN RE
Slide 11: Natural Killer Cell Therapies
CHM 0201, 0301, 1301, 2301, 3301 Natural Killer Cell Therapies For personal use only
Slide 12: Off the Shelf (Allogeneic) NK Therapy Development
OFF THE SHELF (ALLOGENEIC) NK THERAPY DEVELOPMENT ON DEMAND THERAPY For personal use only Leukapheresis (blood draw) Isolation of the Engineering of the 1000’s of Doses Off the Shelf Availability for from a healthy donor Natural Killer Cells Natural Killer Cells Manufactured at Once Patients on Dema
Slide 13: CHM 0201 Phase 1 Study Results
CHM 0201 PHASE 1 STUDY RESULTS PROMISING RESULTS ACROSS ALL KEY ENDPOINTS For personal use only EFFICACY IN EFFICACY IN SAFETY PERSISTENCE EXPANSION SOLID BLOOD TUMOURS CANCERS ESTABLISHED 33% DISEASE 100% DISEASE SAFETY 28 DAY CONTROL RATE CONTROL RATE LARGE SCALE across 3 Dose IN SOLID IN BLOOD PE
Slide 14: CORE NK (CHM 0201) Phase 1 Study Results
CORE NK (CHM 0201) PHASE 1 STUDY RESULTS ONGOING COMPLETE RESPONSE For personal use only PATIENT #8 CORE NK COMPLETE 33-year-old female INFUSION RESPONSE DIAGNOSIS: AML with therapy DAY 0, 14 DAY 100 related High-Risk MDS with CORE NK cell treatment at Enabling patient to circulating blasts and high
Slide 15: Enhancing the CHM 0201 Efficacy Signal
ENHANCING THE CHM 0201 EFFICACY SIGNAL FDA APPROVED FIRST EVER TRIAL OF NK CELLS WITH NEW PHASE 1B CHM 0201 CLINICAL TRIAL VACTOSERTIB For personal use only To identify a combination therapy that could enhance the initial efficacy A Phase Ib Study to Evaluate signal seen with CHM 0201 (CORE NK) cell
Slide 16: CHM 1101 CLTX CAR T Cell Therapy
CHM 1101 CLTX CAR T Cell Therapy For personal use only
Slide 17: Personalized (Autologous) T Cell Therapy Development
PERSONALIZED (AUTOLOGOUS) T CELL THERAPY DEVELOPMENT HARNESSING AN INDIVIDUAL’S OWN IMMUNE SYSTEM For personal use only John John Leukapheresis (blood draw) Isolation of the Engineering of the Individual patients Personalized therapy for from an individual patient T Cells T Cells with Chimeric engin
Slide 18: CHM 1101 (CLTX CAR T) Encouraging Initial Data in Glioblastoma
CHM 1101 (CLTX CAR T) Encouraging Initial Data in Glioblastoma For personal use only Early Signs of Efficacy with Local Administration Post-CLTX CAR T 7 infusions § 70% Disease Nov 4, 2020 No recurrence Control Rate of CHM 1101 “This preliminary data is encouraging as it demonstrates treated § Up to
Slide 19: CHM 2101 CDH17 CAR T Cell Therapy
CHM 2101 For personal use only CDH17 CAR T Cell Therapy
Slide 20: CHM 2101 (CDH17 CAR T): A Novel 3rd Generation CAR T
CHM 2101: (CDH17 CAR T) A NOVEL 3rd GENERATION CAR T DESIGNED FOR SOLID TUMORS AND HEADED TO THE CLINIC For personal use only Preclinical data featured in Nature Cancer Efficacy Safety Complete eradication of tumor High tumor-specific activity in vivo with cells with no relapse no on-target / off-tu
Slide 21: Australia's Most Robust and Advanced Cell Therapy Portfolio and Pipeline
AUSTRALIA’S MOST ROBUST AND ADVANCED CELL THERAPY PORTFOLIO AND PIPELINE For personal use only JAN. 2021 NOV. 2022 1 7 ASSET IN ASSETS IN DEVELOPMENT DEVELOPMENT 1 3 ONGOING CLINICAL ONGOING CLINICAL TRIAL TRIALS 0 2 TRIALS WITH EARLY TRIALS WITH EARLY POSITIVE CLINICAL POSITIVE CLINICAL SIGNALS SIG
Slide 22: Milestones: Next 6-12 Months
CHM 2101 FDA IND Clearance CHM 2101 Manufacture & Release of CDH17 Vector For personal use only CHM 1101 Completion of GBM Phase 1 Dose Escalation MILESTONES NEXT 6-12 CHM 1101 Second CHM GBM Trial Site Initiation MONTHS CHM 1101 First Patient Dosed CHM GBM Trial CHM 1101 Initiation of CHM Ph. 1A/B
Slide 23: Australian Leadership in Cell Therapy
Australian For personal use only Leadership in Cell Therapy Opportunity Clinical Promise Near Term Value Proven Expertise 7 novel assets in the Initial positive Multiple key clinical World class team fast-growing segment signals from 2 milestones over the with success driving in oncology drug phase
Slide 24: Contact Information
For personal use only CONTACT INFORMATION Jennifer Chow Chief Executive Officer Chimeric Therapeutics Ltd Cell: +1 908-723-8387 jchow@chimerictherapeutics.com Paul A. Hopper Executive Chairman Chimeric Therapeutics Ltd Cell: +61 406671515 paulhopper@lifescienceportfolio.com
Chimeric Therapeutics — Shareholder Meeting (November 2022) on 6ix